<--GAT-->

Long-Acting Insulins Approved by FDA

by U.S. Medicine

October 11, 2015

PLAINSBORO, NJ – Physicians treating diabetes patients have new weapons in their arsenal.

The Food and Drug Administration recently approved Tresiba (insulin degludec injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection) to improve glucose control in adults with diabetes mellitus.

Both drugs are manufactured by Novo Nordisk in Plainsboro, NJ.

“Long-acting insulins play an essential role in the treatment of patients with type 1 diabetes and in patients with type 2 diabetes with advanced disease,” said Jean-Marc Guettier, MD, director of the Division of Metabolism and Endocrinology Products in the FDA’s Center for Drug Evaluation and Research. “The FDA remains committed to support the development of innovative therapies for the treatment of diabetes.”

Tresiba is a long-acting insulin analog indicated to improve glycemic control in adults with type 1 and 2 diabetes mellitus. Dosing of Tresiba, which is administered subcutaneously once daily at any time of day, should be individualized based on the patient’s needs, according to the FDA.

Ryzodeg 70/30 is a mixture of insulin degludec, a long-acting insulin analog, and insulin aspart, a rapid-acting human insulin analog. It is indicated to improve glycemic control in adults with diabetes mellitus. 

The FDA warned that Tresiba and Ryzodeg should not be used in those who have diabetic ketoacidosis. It also cautioned that the drugs can cause potentially life-threatening hypoglycemia, adding, “Patients should be monitored more closely with changes to insulin dosage, co-administration of other glucose-lowering medications, meal pattern, physical activity, and in patients with renal impairment or hepatic impairment or hypoglycemia unawareness.”


Comments are closed here.


Related Articles

PhARMD Program Continues to Expand Pharmacists’ Clinical Role in VA

A tool developed by the VA has raised the profile of pharmacists as critical members of patient care teams at the VA, leading to a doubling of the number of pharmacists serving as providers.

Caution Urged in Use of Sulfonylureas in Some T2 Diabetes Patients with CAD

VA clinicians should exercise caution with use of sulfonylurea in some patients with co-morbid type 2 diabetes and cardiovascular disease, according to new research.


U.S. Medicine Recommends


More From fda news

FDA News

VA Study Addresses Concerns About Anti-Epileptic Drugs, Suicidal Behavior Link

In 2008, the U.S. Food and Drug Administration issued an alert about increased risk for suicidal ideation and behavior for patients taking anti-epileptic drugs (AEDs).

FDA News

FDA Approves Option for Schizophrenia, Bipolar Treatment

PALM BEACH GARDENS, FL—A tool developed by the VA has raised the profile of pharmacists as critical members of patient care teams at the VA, leading to a doubling of the number of pharmacists serving... View Article

FDA News

New DHA Screening Process Brings Drug Compounding Costs to 2% of April Levels

PALM BEACH GARDENS, FL—A tool developed by the VA has raised the profile of pharmacists as critical members of patient care teams at the VA, leading to a doubling of the number of pharmacists serving... View Article

FDA News

FDA Approves Tecfidera for Treatment of Relapsing MS

PALM BEACH GARDENS, FL—A tool developed by the VA has raised the profile of pharmacists as critical members of patient care teams at the VA, leading to a doubling of the number of pharmacists serving... View Article

FDA News

Stivarga Approved for Some Stromal Tumors After Use of First-Line Therapies

PALM BEACH GARDENS, FL—A tool developed by the VA has raised the profile of pharmacists as critical members of patient care teams at the VA, leading to a doubling of the number of pharmacists serving... View Article

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up